***Salmonella*, *Campylobacter* and genetic characterisation**

TEST FORMS

|  |
| --- |
| Name:      Name of laboratory:      Name of institute:      City:      Country:      E-mail:      Fax:       |

#### Comments:

####

#### **TEST FORM**

Does your laboratory have an accreditation for performing *Salmonella* AST? [ ]  Yes [ ]  No

Which method did you use for antimicrobial susceptibility testing of *Salmonella* in this EQAS:

 [ ]  Broth microdilution

 Brand of microbroth plates/agar**:**

 Incubation conditions:      °C/     h

How many *Salmonella* isolates does your laboratory annually isolate:

How many *Salmonella* isolates does your laboratory annually test for antimicrobial susceptibility by a MIC method:

Which method was followed for the preparation of the inoculum (please describe)

* Which standard was followed (TREK, CLSI…)
* Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)
* Please describe in detail how you prepared the dilution of the inoculum (including the volume in final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 McFarland solution in 10ml MH broth, for an expected inoculum of 1\*105 CFU/ml)

Comments or additional information:

**TEST FORM**

Does your laboratory have an accreditation for *Campylobacter* AST? [ ]  Yes [ ]  No

Incubation conditions: [ ]  36-37ºC / 48h [ ]  42ºC / 24h

Method used for antimicrobial susceptibility testing of *Campylobacter* in this EQAS:

[ ]  Broth microdilution

Brand of microbroth plates/agar:

How many *Campylobacter* isolates does your laboratory annually isolate:

How many *Campylobacter* isolates does your laboratory annually susceptibility test:

Which method was followed for the preparation of the inoculum (please describe)

* Which standard was followed (TREK, CLSI…)
* Which solvent was used for the preparation of the 0.5 McFarland solution (water, saline)
* Please describe in detail how you prepared the dilution of the inoculum (including the volume in final MH-dilution and intended dilution level; e.g. diluted 1:1000 by adding 10µl of 0.5 McFarland solution in 10ml MH broth, for an expected inoculum of 1\*105 CFU/ml)

Comments or additional information:

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.1 | Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.1 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid (F/C) |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid (T/C) |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  Presumptive ESBL[ ]  Presumptive ESBL+ AmpC | [ ]  Presumptive AmpC[ ]  Presumptive Carbapenemase | [ ]  Other phenotype[ ]  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.2 | Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.2 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid (F/C) |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid (T/C) |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  Presumptive ESBL[ ]  Presumptive ESBL+ AmpC | [ ]  Presumptive AmpC[ ]  Presumptive Carbapenemase | [ ]  Other phenotype[ ]  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.3 | Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.3 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid (F/C) |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid (T/C) |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  Presumptive ESBL[ ]  Presumptive ESBL+ AmpC | [ ]  Presumptive AmpC[ ]  Presumptive Carbapenemase | [ ]  Other phenotype[ ]  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.4 | Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.4 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid (F/C) |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid (T/C) |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  Presumptive ESBL[ ]  Presumptive ESBL+ AmpC | [ ]  Presumptive AmpC[ ]  Presumptive Carbapenemase | [ ]  Other phenotype[ ]  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.5 | Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.5 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid (F/C) |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid (T/C) |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  Presumptive ESBL[ ]  Presumptive ESBL+ AmpC | [ ]  Presumptive AmpC[ ]  Presumptive Carbapenemase | [ ]  Other phenotype[ ]  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.6 | Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.6 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid (F/C) |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid (T/C) |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  Presumptive ESBL[ ]  Presumptive ESBL+ AmpC | [ ]  Presumptive AmpC[ ]  Presumptive Carbapenemase | [ ]  Other phenotype[ ]  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.7 | Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
|  / > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.7 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid (F/C) |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid (T/C) |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  Presumptive ESBL[ ]  Presumptive ESBL+ AmpC | [ ]  Presumptive AmpC[ ]  Presumptive Carbapenemase | [ ]  Other phenotype[ ]  Susceptible |

#### Comments (include optional genotype or other results):

**TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
| > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.8 | Ampicillin, AMP       |       |       |       |
| Azithromycin, AZI |       |       |       |
| Cefotaxime, FOT  |       |       |       |
| Ceftazidime, TAZ  |       |       |       |
| Chloramphenicol, CHL  |       |       |       |
| Ciprofloxacin CIP       |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN  |       |       |       |
| Meropenem, MERO |       |       |       |
| Nalidixic acid, NAL  |       |       |       |
| Sulfamethoxazole, SMX  |       |       |       |
| Tetracycline, TET  |       |       |       |
| Tigecycline, TGC |       |       |       |
| Trimethoprim, TMP  |       |       |       |

All strains resistant to cefotaxime (FOT), ceftazidime (TAZ) or meropenem (MERO) must be included for testing in the second panel as part of confirmatory tests for ESBL-, AmpC or carbapenemase production. See further description in the protocol section ‘3.3.1 *Salmonella*’.

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Results and interpretation |
| > | MIC-value (μg/ml) | S / R |
| *Salmonella* EURL S. 13.8 | Cefepime, FEP |       |       |       |
| Cefotaxime, FOT |       |       |       |
| Cefotaxime + clavulanic acid (F/C) |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, TAZ |       |       |       |
| Ceftazidime+ clavulanic acid (T/C) |       |       |       |
| Ertapenem, ETP |       |       |       |
| Imipenem, IMI |       |       |       |
| Meropenem, MERO |       |       |       |
| Temocillin, TRM |       |       |       |

**Interpretation of PANEL 2 results**:

|  |  |  |
| --- | --- | --- |
| [ ]  Presumptive ESBL[ ]  Presumptive ESBL+ AmpC | [ ]  Presumptive AmpC[ ]  Presumptive Carbapenemase | [ ]  Other phenotype[ ]  Susceptible |

#### Comments (include optional genotype or other results):

#### **TEST FORM**

Antimicrobial susceptibility testing of reference strain *E. coli* ATCC 25922

|  |  |  |
| --- | --- | --- |
|  | Antimicrobial  | MIC-value (μg/ml) |
| 1st panel | Ampicillin, AMP  |       |
| Azithromycin, AZI |       |
| Cefotaxime, FOT |       |
| Ceftazidime, TAZ |       |
| Chloramphenicol, CHL |       |
| Ciprofloxacin, CIP |       |
| Colistin, COL |       |
| Gentamicin, GEN |       |
| Meropenem, MERO |       |
| Nalidixic acid, NAL |       |
| Sulfamethoxazole, SMX\* |       |
| Tetracycline, TET |       |
| Tigecycline, TGC |       |
| Trimethoprim, TMP |       |
| 2nd panel | Cefepime, FEP |       |
| Cefotaxime, FOT |       |
| Cefotaxime + clavulanic acid (F/C) |       |
| Cefoxitin, FOX |       |
| Ceftazidime, TAZ |       |
| Ceftazidime+ clavulanic acid (T/C) |       |
| Ertapenem, ETP |       |
| Imipenem, IMI |       |
| Meropenem, MERO |       |
| Temocillin, TRM |       |

\* for the testing of the *E. coli* ATCC25922 reference strain, sulfamethoxazole and sulfisoxazole, are regarded as comparable, i.e. the obtained MIC-value from the testing of sulfamethoxazole will be evaluated against the acceptance range listed in CLSI M100 for sulfisoxazole (CLSI M100, Table 3).

#### **TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Interpretation |
| MIC-value (μg/ml) | S / R |
| *Campylobacter*EURL C-13.1 [ ]  *C. jejuni* [ ]  *C. coli* | Ciprofloxacin |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Nalidixic acid |       |       |
| Streptomycin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL C-13.2 [ ]  *C. jejuni* [ ]  *C. coli* | Ciprofloxacin |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Nalidixic acid |       |       |
| Streptomycin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL C-13.3 [ ]  *C. jejuni* [ ]  *C. coli* | Ciprofloxacin |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Nalidixic acid |       |       |
| Streptomycin |       |       |
| Tetracycline |       |       |
| *Campylobacter*EURL C-13.4 [ ]  *C. jejuni* [ ]  *C. coli* | Ciprofloxacin |       |       |
| Erythromycin |       |       |
| Gentamicin |       |       |
| Nalidixic acid |       |       |
| Streptomycin |       |       |
| Tetracycline |       |       |

####

#### **TEST FORM**

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Interpretation |
| MIC-value (μg/ml) | S / R |
| *Campylobacter*EURL C-13.5 [ ]  *C. jejuni* [ ]  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*EURL C-13.6 [ ]  *C. jejuni* [ ]  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*EURL C-13.7 [ ]  *C. jejuni* [ ]  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |
| *Campylobacter*EURL C-13.8 [ ]  *C. jejuni* [ ]  *C. coli* | Ciprofloxacin |  |  |
| Erythromycin |  |  |
| Gentamicin |  |  |
| Nalidixic acid |  |  |
| Streptomycin |  |  |
| Tetracycline |  |  |

#### **TEST FORM**

Susceptibility testing of *Campylobacter jejuni* reference strain ATCC 33560

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | MIC-value (μg/ml) |
| 36 °C/48 hours | 42 °C/24 hours |
| *C. jejuni* ATCC 33560 | Ciprofloxacin |       |       |
| Erythromycin |       |       |
| Nalidixic acid |       |       |
| Tetracycline |       |       |

**For Agar dilution:**

 Susceptibility testing of *Campylobacter jejuni* reference strain ATCC 33560

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | MIC-value (μg/ml) |
| *C. jejuni* ATCC 33560 | Ciprofloxacin |       |
| Erythromycin  |       |
| Gentamicin |       |
| Nalidixic acid  |       |
| Tetracycline |       |

#### **TEST FORM – genotypic characterisation**

Genotypic characterisation of the test strains

|  |  |
| --- | --- |
| Strain code:       | Method used:      If PCR-methods, additional information should be given below |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |

|  |  |
| --- | --- |
| Strain code:       | Method used:      If PCR-methods, additional information should be given below |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |
| Gene:      [ ]  Found[ ]  Tested, not found | [ ]  Published method , reference:       |
| [ ]  In-house method |
| Primer used 5’→3’:       |
| Primer used 3’→5’:       |

Comments: